Monitor for takedowns under the ATM facility or any follow-on offering, which would crystallize dilution. The company's cash runway and pipeline milestones will determine the pace of capital deployment.
FATE drugs
FATE drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $1.28entry
- T+1 · 18h ago −10.94%α −9.03% · $1.14
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fate Therapeutics' universal shelf registration (S-3, File No. 333-299862) became effective on November 12, 2026, enabling the company to sell up to $300M in securities including a $100M ATM facility. As a pre-revenue clinical-stage biotech with $139.1M cash and ongoing net losses, this effectiveness signals potential near-term dilution to fund pipeline development.
Key Facts
- Shelf registration (File No. 333-299862) became effective on November 12, 2026
- Shelf registers up to $300M in securities including a $100M ATM facility with Leerink Partners
- Company had $139.1M cash as of September 30, 2026
- Pre-revenue clinical-stage biotech with Q3 2026 net loss of $0.25 per share
- Normal daily move for FATE is 5.8% (30-day volatility)
Financial Impact
Up to $300M in potential dilution; $100M ATM facility can be drawn at any time
Risk Factors
- Immediate dilution risk if company draws on ATM facility or conducts a follow-on offering
- Pre-revenue status with ongoing net losses increases dependence on capital markets
- Shelf effectiveness removes regulatory barrier to rapid equity issuance
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003536 |
| Document: 9999999995-26-003536-index.html | 9999999995-26-003536 |
| Document: 9999999995-26-003536.txt | 9999999995-26-003536 |
Track record
21 reports on FATE
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Viewing Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers